RB in breast cancer

At the crossroads of tumorigenesis and treatment

Emily E. Bosco, Erik S. Knudsen

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Cancer is a highly heterogeneous disease, wherein specific determinants modulate disease severity and therapeutic outcomes. In breast cancer, significant effort has been channeled into defining critical genetic effectors of disease behavior. One key molecular determinant is the retinoblastoma tumor suppressor (RB), which is functionally inactivated in the majority of human cancers, and aberrant in nearly half of breast cancers. Deficiency in RB function compromises cell cycle checkpoints, contributes to aggressive tumor proliferation, and is associated with advanced disease. Recent investigation indicates that RB-deficiency has dramatic and disparate effects on the response to therapeutic modalities utilized in the treatment of breast cancer. Loss of RB function promotes inappropriate cell cycle progression during therapeutic challenge. In the context of cytotoxic therapies, this lack of checkpoint function leads to increased sensitivity to the agent. However, RB-deficiency efficiently bypasses the anti-mitogenic function of hormonal therapies and is associated with early disease recurrence following tamoxifen therapy. Thus, RB-pathway status has powerful effects on both tumorigenic proliferation and therapeutic response, and may represent a critical basis for informing breast cancer therapy.

Original languageEnglish (US)
Pages (from-to)667-671
Number of pages5
JournalCell Cycle
Volume6
Issue number6
StatePublished - Mar 15 2007

Fingerprint

Carcinogenesis
Breast Neoplasms
Tumors
Cells
Therapeutics
Tamoxifen
Neoplasms
Inborn Genetic Diseases
Retinoblastoma
Cell Cycle Checkpoints
Cell Cycle
Recurrence

Keywords

  • Breast cancer
  • DNA damage
  • E2F
  • RB
  • Tamoxifen

ASJC Scopus subject areas

  • Cell Biology
  • Biochemistry
  • Molecular Biology

Cite this

Bosco, E. E., & Knudsen, E. S. (2007). RB in breast cancer: At the crossroads of tumorigenesis and treatment. Cell Cycle, 6(6), 667-671.

RB in breast cancer : At the crossroads of tumorigenesis and treatment. / Bosco, Emily E.; Knudsen, Erik S.

In: Cell Cycle, Vol. 6, No. 6, 15.03.2007, p. 667-671.

Research output: Contribution to journalArticle

Bosco, EE & Knudsen, ES 2007, 'RB in breast cancer: At the crossroads of tumorigenesis and treatment', Cell Cycle, vol. 6, no. 6, pp. 667-671.
Bosco, Emily E. ; Knudsen, Erik S. / RB in breast cancer : At the crossroads of tumorigenesis and treatment. In: Cell Cycle. 2007 ; Vol. 6, No. 6. pp. 667-671.
@article{67acadbf3c56440a9797a5675f69fca9,
title = "RB in breast cancer: At the crossroads of tumorigenesis and treatment",
abstract = "Cancer is a highly heterogeneous disease, wherein specific determinants modulate disease severity and therapeutic outcomes. In breast cancer, significant effort has been channeled into defining critical genetic effectors of disease behavior. One key molecular determinant is the retinoblastoma tumor suppressor (RB), which is functionally inactivated in the majority of human cancers, and aberrant in nearly half of breast cancers. Deficiency in RB function compromises cell cycle checkpoints, contributes to aggressive tumor proliferation, and is associated with advanced disease. Recent investigation indicates that RB-deficiency has dramatic and disparate effects on the response to therapeutic modalities utilized in the treatment of breast cancer. Loss of RB function promotes inappropriate cell cycle progression during therapeutic challenge. In the context of cytotoxic therapies, this lack of checkpoint function leads to increased sensitivity to the agent. However, RB-deficiency efficiently bypasses the anti-mitogenic function of hormonal therapies and is associated with early disease recurrence following tamoxifen therapy. Thus, RB-pathway status has powerful effects on both tumorigenic proliferation and therapeutic response, and may represent a critical basis for informing breast cancer therapy.",
keywords = "Breast cancer, DNA damage, E2F, RB, Tamoxifen",
author = "Bosco, {Emily E.} and Knudsen, {Erik S.}",
year = "2007",
month = "3",
day = "15",
language = "English (US)",
volume = "6",
pages = "667--671",
journal = "Cell Cycle",
issn = "1538-4101",
publisher = "Landes Bioscience",
number = "6",

}

TY - JOUR

T1 - RB in breast cancer

T2 - At the crossroads of tumorigenesis and treatment

AU - Bosco, Emily E.

AU - Knudsen, Erik S.

PY - 2007/3/15

Y1 - 2007/3/15

N2 - Cancer is a highly heterogeneous disease, wherein specific determinants modulate disease severity and therapeutic outcomes. In breast cancer, significant effort has been channeled into defining critical genetic effectors of disease behavior. One key molecular determinant is the retinoblastoma tumor suppressor (RB), which is functionally inactivated in the majority of human cancers, and aberrant in nearly half of breast cancers. Deficiency in RB function compromises cell cycle checkpoints, contributes to aggressive tumor proliferation, and is associated with advanced disease. Recent investigation indicates that RB-deficiency has dramatic and disparate effects on the response to therapeutic modalities utilized in the treatment of breast cancer. Loss of RB function promotes inappropriate cell cycle progression during therapeutic challenge. In the context of cytotoxic therapies, this lack of checkpoint function leads to increased sensitivity to the agent. However, RB-deficiency efficiently bypasses the anti-mitogenic function of hormonal therapies and is associated with early disease recurrence following tamoxifen therapy. Thus, RB-pathway status has powerful effects on both tumorigenic proliferation and therapeutic response, and may represent a critical basis for informing breast cancer therapy.

AB - Cancer is a highly heterogeneous disease, wherein specific determinants modulate disease severity and therapeutic outcomes. In breast cancer, significant effort has been channeled into defining critical genetic effectors of disease behavior. One key molecular determinant is the retinoblastoma tumor suppressor (RB), which is functionally inactivated in the majority of human cancers, and aberrant in nearly half of breast cancers. Deficiency in RB function compromises cell cycle checkpoints, contributes to aggressive tumor proliferation, and is associated with advanced disease. Recent investigation indicates that RB-deficiency has dramatic and disparate effects on the response to therapeutic modalities utilized in the treatment of breast cancer. Loss of RB function promotes inappropriate cell cycle progression during therapeutic challenge. In the context of cytotoxic therapies, this lack of checkpoint function leads to increased sensitivity to the agent. However, RB-deficiency efficiently bypasses the anti-mitogenic function of hormonal therapies and is associated with early disease recurrence following tamoxifen therapy. Thus, RB-pathway status has powerful effects on both tumorigenic proliferation and therapeutic response, and may represent a critical basis for informing breast cancer therapy.

KW - Breast cancer

KW - DNA damage

KW - E2F

KW - RB

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=34047237893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047237893&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 667

EP - 671

JO - Cell Cycle

JF - Cell Cycle

SN - 1538-4101

IS - 6

ER -